CLOs on the Move

Profusa

www.profusa.com

 
Profusa, Inc. is leading the development of a new generation of biologically integrated sensors that empowers an individual with the ability to continuously monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Overcoming the bodys response to foreign material, the companys technology enables the development of minute bioengineered sensors that become one with the body to detect and transmit clinical-grade data for personal and medical use.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million
  • www.profusa.com
  • 345 Allerton Ave South
    San Francisco, CA USA 94080
  • Phone: 415.655.9861

Executives

Name Title Contact Details

Similar Companies

Canadian Hospital Specialties

Canadian Hospital Specialties Ltd is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NewScience

NewScience is a Canton, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reliable Medical Supply

Reliable Medical Supply is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trice Medical

Trice Medical was founded to fundamentally improve orthopedic diagnostics. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians office. Our mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.